Product Pipeline

Product Pipeline – thinking each of you

“Brightening the future of people facing challenges of cancers.”

Solasia has been developing a wide range of products varying from pharmaceuticals for cancer
therapy to supportive care for adverse event of drugs.

Development Strategy

  • Solasia
  • Other Companies

Pharmaceuticals

    • Pipeline Code
    • Estimated Initial Indication
    • Originator
  • Pre-
    clinical
  • Clinical
    Study
    Phase 1
  • Clinical
    Study
    Phase 2
  • Clinical
    Study
    Phase 3
  • NDA
  • Approval
  • Launch
  • Partner
  • SP-01

    Chemotherapy Induced Nausea and Vomiting

    ProStrakan(Kyowa Kirin)
    overview
  • China (Beijing, Shanghai, Guangzhou : own sales area)
    Taiwan, Hong Kong etc. (Kyowa Kirin : Sublicensee)
  • Lee’s Pharma:
    China Mainland w/o Beijing, Shanghai, Guangzhou, Hong Kong and Macau
    Kyowa Kirin:
    Taiwan, Hong Kong etc.
  • SP-02

    Peripheral T-Cell Lymphoma

    ZIOPHARM Oncology, Inc
    overview
  • Japan, Korea, Taiwan, HK (Pivotal PII study completion: Achieved primary endpoint, preparation for NDA filing)
    China (Phase II/III, pivotal study preparation)
    US (Phase IIA, completion)
    EU (Pre-clinical, completion)
  • Meiji Seika Pharma:
    Japan
    HB Human BioScience SAS:
    Latin America
  • SP-04

    Chemotherapy Induced Peripheral Neuropathy (CIPN)

    Egetis Therapeutics AB
    overview
  • Japan, South Korea, Taiwan, HK (Phase III, Completion)
    China
    US and EU (Phase III, Completion by Egetis)
  • Maruho Co., Ltd.:
    Japan
  • SP-05

    Increase efficacy of fluorouracil

    Isofol Medical AB
    overview
  • Japan(Global Phase III)
    US, Canada, EU, Australia(Global Phase III by Isofol)

Medical Device

    • Pipeline Code
    • Estimated Initial indication
    • Originator
  • Pre-
    clinical
  • Clinical Study
  • NMDA
  • Approval
  • Launch
  • Partner
  • SP-03

    Pain associated oral mucositis

    Camurus AB
    overview
  • Japan
    China (Beijing, Shanghai, Guangzhou : own sales area)
    South Korea
  • Meiji Seika Pharma:
    Japan
    Lee’s Pharma:
    China Mainland w/o Beijing, Shanghai, Guangzhou and Taiwan
    Synex:
    South Korea

New Drug Candidates

  • Nucleic acid drug candidate for peritoneal metastases (disseminated metastases developing in the peritoneum): Option agreement for in-license of worldwide rights with GeneCare Research Institute Co., Ltd.
  • New drug candidates for rare disease and/or oncology based on RNA editing technology utilizing pentatricopeptide repeat (PPR) protein platform technology: Joint R&D agreement with EditForce Inc.

Pharmaceuticals

Pipeline Code
SP-01
Estimated Initial indication
Chemotherapy Induced Nausea and Vomiting
Originator
ProStrakan(Kyowa Kirin)
overview
  • Pre-
    clinical
  • Clinical
    Study
    Phase 1
  • Clinical
    Study
    Phase 2
  • Clinical
    Study
    Phase 3
  • NDA
  • App-
    roval
  • Lau-
    nch
China (Beijing, Shanghai, Guangzhou : own sales area)
Taiwan, Hong Kong etc. (Kyowa Kirin : Sublicensee)
Partner
Lee’s Pharma
China Mainland w/o Beijing, Shanghai, Guangzhou, Hong Kong and Macau
Kyowa Kirin
Taiwan, Hong Kong etc.
Pipeline Code
SP-02
Estimated Initial indication
Peripheral T-Cell Lymphoma
Originator
ZIOPHARM Oncology, Inc
overview
  • Pre-
    clinical
  • Clinical
    Study
    Phase 1
  • Clinical
    Study
    Phase 2
  • Clinical
    Study
    Phase 3
  • NDA
  • App-
    roval
  • Lau-
    nch
Japan, Korea, Taiwan, HK (Pivotal PII study completion: Achieved primary endpoint, preparation for NDA filing)
China (Phase II/III, pivotal study preparation)
US (Phase IIA, completion)
EU (Pre-clinical, completion)
Partner
Meiji Seika Pharma
Japan
HB Human BioScience SAS
Latin America
Pipeline Code
SP-04
Estimated Initial indication
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Originator
Egetis Therapeutics AB
overview
  • Pre-
    clinical
  • Clinical
    Study
    Phase 1
  • Clinical
    Study
    Phase 2
  • Clinical
    Study
    Phase 3
  • NDA
  • App-
    roval
  • Lau-
    nch
Japan, South Korea, Taiwan, HK (Phase III, Completion)
China
US and EU (Phase III, Completion by Egetis)
Partner
Maruho Co., Ltd.
Japan
Pipeline Code
SP-05
Estimated Initial indication
Increase efficacy of fluorouracil
Originator
Isofol Medical AB
overview
  • Pre-
    clinical
  • Clinical
    Study
    Phase 1
  • Clinical
    Study
    Phase 2
  • Clinical
    Study
    Phase 3
  • NDA
  • App-
    roval
  • Lau-
    nch
Japan(Global Phase III)
US, Canada, EU, Australia(Global Phase III by Isofol)
Partner

Medical Device

Pipeline Code
SP-03
Estimated Initial indication
Pain associated oral mucositis
Originator
Camurus AB
overview
  • Pre-
    clinical
  • Clinical Study
  • NMDA
  • Approval
  • Launch
Japan
China (Beijing, Shanghai, Guangzhou : own sales area)
South Korea
Partner
Meiji Seika Pharma
Japan
Lee’s Pharma
China Mainland w/o Beijing, Shanghai, Guangzhou and Taiwan
Synex
South Korea

New Drug Candidates

  • Nucleic acid drug candidate for peritoneal metastases (disseminated metastases developing in the peritoneum): Option agreement for in-license of worldwide rights with GeneCare Research Institute Co., Ltd.
  • New drug candidates for rare disease and/or oncology based on RNA editing technology utilizing pentatricopeptide repeat (PPR) protein platform technology: Joint R&D agreement with EditForce Inc.

Information for use of our products

The site you are about to access is intended to provide information for medical professionals in Japan. It is designed to allow users to better understand Solasia's products.

I have read and understood above

Page Top

SELECT YOUR LANGUAGE